The Human Epidermal Growth Factor Receptor 2 Screening Tests for Breast Cancer Suggested by the New Updated Recommendation of the American Society of Clinical Oncology/College of American Pathologists Will Involve a Rise of the In-Situ Hybridization Tests for the European Laboratories of Pathology

<table>A 91-year-old woman with ductal breast carcinoma. IHC classified 2+ with the 2007 ASCO/CAP recommendation and 3+ with the 2013 ASCO/CAP version. Ratio between HER2 (red) and CEN-17 (green) is 5.3. FISH is positive for the 2007 system and positive for the 2013. HER2 IHC (Clone A0485, Dako, 200x magnification) and HER2 FISH (HER2 IQFISH pharm DX, Dako, 1000x magnification).</table>

International Scholarly Research Notices

fig4

Figure 4

Figure 4: The Human Epidermal Growth Factor Receptor 2 Screening Tests for Breast Cancer Suggested by the New Updated Recommendation of the American Society of Clinical Oncology/College of American Pathologists Will Involve a Rise of the In-Situ Hybridization Tests for the European Laboratories of Pathology 

Figure 4 | The Human Epidermal Growth Factor Receptor 2 Screening Tests for Breast Cancer Suggested by the New Updated Recommendation of the American Society of Clinical Oncology/College of American Pathologists Will Involve a Rise of the In-Situ Hybridization Tests for the European Laboratories of Pathology 